AlphAIAlphAI — Financial news for AI agents
globenewswire.comOCT 82 min read

Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.

Original reporting
globenewswire.com
Published Oct 8, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation — source image
Source · globenewswire.com
Decision brief

The 30-second read

Low
01

Why it matters

The disclosed data suggest continued safety and potential efficacy, which may improve investor sentiment and support future financing for the upcoming Phase 2b study.

02

Market read

The announcement provides fresh clinical‑trial information that could influence biotech investors, though impact is likely confined to the sector.

03

What to watch

Regulatory timeline and competition from other fibrosis drugs could temper upside.

Relevance 8/10Novelty 8/10Timing: presentation at UEG Week on Oct 20

Background

Agomab Therapeutics announced that open‑label extension data from its Phase 2a STENOVA study in fibro‑stenosing Crohn’s disease will be presented at UEG Week 2026 and that the results support launching a Phase 2b NOV‑ERA trial.

Market effects

Sector

May signal progress for fibro‑inflammation therapeutics and could boost interest in similar biotech pipelines.

Regional

Limited to European biotech investors; no broad regional effect expected.

Global

Relevant to global biotech sector but unlikely to move major indices.

Counterpoint

What could challenge this read

If OLE data are modest, the hype could lead to overvaluation of Agomab.

Key entities

  • Company
    Agomab Therapeutics NV

    Clinical‑stage biopharma developing ontunisertib for fibro‑inflammatory diseases.

  • Drug
    Ontunisertib (AGMB-129)

    Oral ALK5 inhibitor being evaluated in Crohn’s disease.

Read at source← All news

Related articles

OCT 14
$AGMBMedAI 8/10

Agomab Doses First Patient In Phase 2b Ontunisertib Trial For Crohn's Disease

AgomAb Therapeutics (AGMB) dosed the first patient in a Phase 2b trial of Ontunisertib for Crohn's disease. The trial aims to enroll 320 adults with symptomatic fibrostenosing Crohn's disease across multiple countries. Ontunisertib has FDA Fast Track Designation and showed positive results in an earlier Phase 2a trial. The study's primary endpoint is endoscopic passability of ileal strictures at Week 24.

rttnews.com2 min
OCT 13
$AGMBMedAI 8/10

Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease

Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.

tipranks.com1 min
OCT 2
$AGMBMedAI 8/10

H.C. Wainwright reiterates Agomab stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.

investing.com2 min
OCT 1
$AGMBMedAI 8/10

Why is Agomab Therapeutics stock sliding today?

Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.

investing.com2 min
OCT 1
$AGMBHighAI 8/10

Agomab stock jumps on positive trial data

Agomab Therapeutics (NASDAQ:AGMB) shares rose 6.3% premarket after positive trial data for ontunisertib in Crohn's disease. The STENOVA extension study showed favorable safety, low event rates, and sustained disease control. 97% of patients were in remission at Week 48. The company plans a Phase 2b study. Ontunisertib has FDA Fast Track Designation.

investing.com2 min